Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

Blood Adv (2021) 5 (19): 3862–3872.

https://doi.org/10.1182/bloodadvances.2021004778

Published: 2021

Includes: Supplemental data

Journal Articles

Optimizing outcomes in primary mediastinal B-cell lymphoma: is R-CHOP enough?

Michael R. Cook, Kieron Dunleavy

Blood Adv (2021) 5 (19): 3873–3875.

https://doi.org/10.1182/bloodadvances.2021005190

Published: 2021

Journal Articles

Fatal late-onset CAR T-cell–mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma

Susanne Jung, Jochen Greiner, Stephanie von Harsdorf, Pavle Popovic, Roland Moll, Jens Schittenhelm, Kosmas Kandilaris, Volker Daniel, Alexander Kunz, Michael Schmitt, Peter Dreger

Blood Adv (2021) 5 (19): 3789–3793.

https://doi.org/10.1182/bloodadvances.2021004889

Published: 2021

Includes: Supplemental data

Journal Articles

Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma

Jennifer L. Crombie, Loretta J. Nastoupil, Robert Redd, Kevin Tang, Geoffrey Shouse, Alex F. Herrera, Victor A. Chow, Mazyar Shadman, Omar Castaneda Puglianini, Anna Saucier, Caron A. Jacobson, Philippe Armand, Gary Simmons

Blood Adv (2021) 5 (18): 3563–3567.

https://doi.org/10.1182/bloodadvances.2021004880

Published: 2021

Journal Articles

Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL

Kallesh D. Jayappa, Vicki L. Gordon, Christopher G. Morris, Briana Wilson, B. Dharmaveer Shetty, Konrad J. Cios, Puja C. Arora, Krista M. Isaac, Shekhar Saha, Timothy P. Bender, Michael E. Williams, Craig A. Portell, Michael J. Weber

Blood Adv (2021) 5 (17): 3497–3510.

https://doi.org/10.1182/bloodadvances.2020003944

Published: 2021

Includes: Supplemental data

Journal Articles

Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1

Blood Adv (2021) 5 (16): 3203–3215.

https://doi.org/10.1182/bloodadvances.2021004976

Published: 2021

Includes: Supplemental data

Journal Articles

Effective anti-BCMA retreatment in multiple myeloma

Nicolas Gazeau, David Beauvais, Ibrahim Yakoub-Agha, Suman Mitra, Timothy B. Campbell, Thierry Facon, Salomon Manier

Blood Adv (2021) 5 (15): 3016–3020.

https://doi.org/10.1182/bloodadvances.2021004176

Published: 2021

Journal Articles

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Blood Adv (2021) 5 (13): 2707–2716.

https://doi.org/10.1182/bloodadvances.2020004155

Published: 2021

Includes: Supplemental data

Journal Articles

Single-cell ATAC-seq reveals GATA2-dependent priming defect in myeloid and a maturation bottleneck in lymphoid lineages

Serine Avagyan, Margaret C. Weber, Sai Ma, Meera Prasad, William P. Mannherz, Song Yang, Jason D. Buenrostro, Leonard I. Zon

Blood Adv (2021) 5 (13): 2673–2686.

https://doi.org/10.1182/bloodadvances.2020002992

Published: 2021

Includes: Supplemental data

Journal Articles

Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma

Karthik Nath, Soi-Cheng Law, Muhammed B. Sabdia, Jay Gunawardana, Lilia M. de Long, David Sester, Mohamed Shanavas, Hennes Tsang, Joshua W. D. Tobin, Sarah-Jane Halliday, Annette Hernandez, Donna Cross, Robert J. Bird, Sanjiv Jain, Colm Keane, Dipti Talaulikar, Judith Trotman, Phillip Law, Maher K. Gandhi

Blood Adv (2021) 5 (12): 2644–2649.

https://doi.org/10.1182/bloodadvances.2020004051

Published: 2021

Includes: Supplemental data

Journal Articles

Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma

Donald L. Patrick, Annette Powers, Monika Parisi Jun, Yeonhee Kim, Jacob Garcia, Christine Dehner, David G. Maloney

Blood Adv (2021) 5 (8): 2245–2255.

https://doi.org/10.1182/bloodadvances.2020003503

Published: 2021

Includes: Supplemental data

Journal Articles

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Lucia Masarova, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Naval G. Daver, Tapan M. Kadia, Helen T. Chifotides, Lingsha Zhou, Gautam Borthakur, Zeev Estrov, Marina Konopleva, Srdan Verstovsek

Blood Adv (2021) 5 (8): 2156–2164.

https://doi.org/10.1182/bloodadvances.2020003934

Published: 2021

Includes: Supplemental data

Journal Articles

Immunotherapy perspectives in the new era of B-cell editing

Natsuko Ueda, Marine Cahen, Yannic Danger, Jérôme Moreaux, Christophe Sirac, Michel Cogné

Blood Adv (2021) 5 (6): 1770–1779.

https://doi.org/10.1182/bloodadvances.2020003792

Published: 2021

Journal Articles

Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial

Jeremy S. Abramson, Tanya Siddiqi, Jacob Garcia, Christine Dehner, Yeonhee Kim, Andy Nguyen, Sophie Snyder, November McGarvey, Matthew Gitlin, Corey Pelletier, Monika P. Jun

Blood Adv (2021) 5 (6): 1695–1705.

https://doi.org/10.1182/bloodadvances.2020003531

Published: 2021

Journal Articles

Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era

Arushi Khurana, Mattia Novo, Grzegorz S. Nowakowski, Kay M. Ristow, Robert J. Spinner, Christopher H. Hunt, Rebecca L. King, Daniel H. Lachance, Thomas M. Habermann, Ivana N. Micallef, Patrick B. Johnston

Blood Adv (2021) 5 (5): 1379–1387.

https://doi.org/10.1182/bloodadvances.2020003666

Published: 2021

Includes: Supplemental data

Journal Articles

Genome-wide interference of ZNF423 with B-lineage transcriptional circuitries in acute lymphoblastic leukemia

Pablo Iglesias, Ann-Christin Puller, Marcos Seoane, Michael Spohn, Sabine Raasch, Marianne Klokow, Jürgen Müller, Lia Burkhardt, Daniela Indenbirken, Martin A. Horstmann

Blood Adv (2021) 5 (5): 1209–1223.

https://doi.org/10.1182/bloodadvances.2020001844

Published: 2021

Includes: Supplemental data

Journal Articles

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

Chaja F. Jacobs, Eric Eldering, Arnon P. Kater

Blood Adv (2021) 5 (3): 913–925.

https://doi.org/10.1182/bloodadvances.2020003768

Published: 2021

Includes: Supplemental data

Journal Articles

Constitutive activation of NF-κB during early bone marrow development results in loss of B cells at the pro-B-cell stage

Andrea Paun, Estefania Claudio, Ulrich K. Siebenlist

Blood Adv (2021) 5 (3): 745–755.

https://doi.org/10.1182/bloodadvances.2020002932

Published: 2021

Includes: Supplemental data

Journal Articles

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

Kodandaram Pillarisetti, Gordon Powers, Leopoldo Luistro, Alexander Babich, Eric Baldwin, Yingzhe Li, Xiaochun Zhang, Mark Mendonça, Nate Majewski, Rupesh Nanjunda, Diana Chin, Kathryn Packman, Yusri Elsayed, Ricardo Attar, François Gaudet

Blood Adv (2020) 4 (18): 4538–4549.

https://doi.org/10.1182/bloodadvances.2020002393

Published: 2020

Includes: Supplemental data

Journal Articles

Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis

Daisuke Kaji, Yasunori Ota, Yasuharu Sato, Koji Nagafuji, Yasunori Ueda, Masataka Okamoto, Yasushi Terasaki, Naoko Tsuyama, Kosei Matsue, Tomohiro Kinoshita, Go Yamamoto, Shuichi Taniguchi, Shigeru Chiba, Koichi Ohshima, Koji Izutsu

Blood Adv (2020) 4 (18): 4442–4450.

https://doi.org/10.1182/bloodadvances.2020002293

Published: 2020

Includes: Supplemental data

NARROW

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

Optimizing outcomes in primary mediastinal B-cell lymphoma: is R-CHOP enough?

Fatal late-onset CAR T-cell–mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma

Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma

Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL

Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1

Effective anti-BCMA retreatment in multiple myeloma

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Single-cell ATAC-seq reveals GATA2-dependent priming defect in myeloid and a maturation bottleneck in lymphoid lineages

Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma

Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Immunotherapy perspectives in the new era of B-cell editing

Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial

Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era

Genome-wide interference of ZNF423 with B-lineage transcriptional circuitries in acute lymphoblastic leukemia

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

Constitutive activation of NF-κB during early bone marrow development results in loss of B cells at the pro-B-cell stage

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only